Retatrutide, a new dual activator of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) receptor , is demonstrating promising outcomes in preliminary clinical trials . Current examination https://infopagex.com/story6799942/retatrutide-emerging-studies-and-possible-therapeutic-applications